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Abstract
Swine production has been an important part of our lives since the late Mesolithic or early
Neolithic periods, and ranks number one in world meat production. Pig production also
contributes to high-value-added medical markets in the form of pharmaceuticals, heart valves, and
surgical materials. Genetic engineering, including the addition of exogenous genetic material or
manipulation of the endogenous genome, holds great promise for changing pig phenotypes for
agricultural and medical applications. Although the first transgenic pigs were described in 1985,
poor survival of manipulated embryos; inefficiencies in the integration, transmission, and
expression of transgenes; and expensive husbandry costs have impeded the widespread
application of pig genetic engineering. Sequencing of the pig genome and advances in reproductive
technologies have rejuvenated efforts to apply transgenesis to swine. Pigs provide a compelling
new resource for the directed production of pharmaceutical proteins and the provision of cells,
vascular grafts, and organs for xenotransplantation. Additionally, given remarkable similarities in
the physiology and size of people and pigs, swine will increasingly provide large animal models of
human disease where rodent models are insufficient. We review the challenges facing pig
transgenesis and discuss the utility of transposases and recombinases for enhancing the success
and sophistication of pig genetic engineering. ‘The paradise of my fancy is one where pigs have
wings.’ (GK Chesterton).
Published: 31 October 2007
Genome Biology 2007, 8(Suppl 1):S13 (doi:10.1186/gb-2007-8-S1-S13)
The electronic version of this article is the complete one and can be
found online at http://genomebiology.com/2007/8/S1/S13
© 2007 BioMed Central Ltd 
Introduction
Pigs are ungulates native to Eurasia collectively grouped
under the genus Sus within the Suidae family. Phylo-
geographic analysis reveals that pigs were domesticated
independently at least seven times around the globe, first at
least 9,000 years ago [1,2]. Our longstanding affinity for pigs
stems from their omnivorous ability to convert even our
scraps into healthy and nutritious pork. Since their
domestication, pigs have also captured our cultural
imagination. Their intelligence and almost human behavior
finds pigs intertwined with us in mythology, language, and
art. The meat pig represents a significant commodity
worldwide, in 2004 producing more than 89 million tons of
meat [3] and contributing more than $50 billion to the US
economy alone [4]. Co-products from hogs play a vital
although less visible role in maintaining and improving the
quality of human life, being the primary source of more than
20 drugs and pharmaceuticals [5]. Pig insulin, which differs
from the human protein by a single amino acid, had saved
the lives of innumerable type 1 diabetic patients before the
development of recombinant human insulin. Pig heart valves
are used to repair damaged or diseased human hearts, and
pig skin is used to treat severe burn victims and to produce
collagen scaffolds, gels, and other surgical materials.
The anthropomorphism of pigs in our culture seems almost
prescient, given what we now know to be extensive simi-
larities between human and pig molecular, cellular, and
systems physiology [6,7]. Pigs were Galen’s preferred models
in his quest for truth about human anatomy during an erathat forbade human dissection [8]. Christian Barnard, who
performed the worlds first heart transplant in 1967, once
remarked that, ‘Strange as it may seem, in several anatomic
aspects the pig is closer to the human being than any other
animal’ [9], a view that motivated the development of the
Minnesota minipig at the Hormel Institute in Austin,
Minnesota [9,10]. Improvements in our ability to
manipulate the pig genome will increase the importance of
pigs in biomedicine, both as models of human disease and as
donors of cells, tissues, and organs for xenotransplantation.
Goals and applications of pig genome
modification
Since their domestication, producers have striven to improve
the performance of pigs by the selection and improvement of
pig genetics, and by engineering of systems for their
production. Significant contemporary efforts are focused on
genetic improvement using genetic marker assisted selection
[11,12] and genetical genomics [13,14]. With the emergence of
technologies for animal transgenesis and genetic engineering,
scientists have also sought to improve the performance or
change the phenotype of pigs based on directed genetic
modification. Agricultural objectives include enhancing
growth and nutrient partitioning [15-17], changing pork
composition [18,19], supplementing milk composition for
piglet consumption [20,21], improving pig resistance to
pathogens [22], and even reducing the environmental impact
of pig waste [23]. Efforts to expand the utility of pigs as
bioreactors for pharmaceutical production have targeted the
expression of therapeutic proteins in their milk [24-26],
blood [27,28], urine [29], and potentially semen [30,31].
A survey of the US National Institutes of Health CRISP
(Computer Retrieval of Information on Scientific Projects)
database reveals that pigs are currently the subjects of more
than 450 active research projects. Among these, a handful
aim to alter pigs genetically and so develop large animal
models of human disease. Nearly a decade ago, a pig model
of retinitis pigmentosa was created by germline transgenesis
with a dominant mutant rhodopsin gene (Pro347Leu) [32].
This model provided important data regarding the earliest
stages in photoreceptor degeneration in this condition.
Contemporary targets include models of arteriosclerosis and
cystic fibrosis [33,34], diseases in which animal size and
physiology diminish the utility of mouse models.
Xenotransplantation - the transplantation of cells, tissue, and
organs from one species to another - may be the most
important application of pig genetic engineering. According
to the United Network for Organ Sharing, nearly 94,000
people are currently on the waiting list for organ transplants
in the USA alone, with only 20% likely to receive this life
saving procedure (Table 1) because of a shortage of suitable
organs or tissues. Targets for the genetic modification of pigs
for xenotransplantation have thus far emphasized reducing
the immunogenicity of pig cells and tissues, and preventing
the hyperacute rejection (HAR) and acute vascular rejection
responses that are observed within minutes and days,
respectively, after transplantation of pig organs to non-
human primates (NHPs).
HAR of porcine organs by old world primate recipients is
mediated through preformed antibodies against galactosyl-
α-1,3-galactose epitopes expressed on the surface of pig
cells. Antigen recognition leads to complement activation
and assembly of membrane attack complexes on the surface
of donor tissue endothelium, causing cell lysis, hemorrhage,
and clotting that occludes the donor tissue blood supply.
Transgenic pigs have been developed that express
regulators of the complement cascade, including CD55
(decay accelerating factor), CD59, and CD46 (membrane
co-factor protein), which are intended to suppress the
assembly of membrane attack complexes on donor tissues
[35-37]. Xenogenic transplants of organs from these pigs
into NHPs have indeed exhibited significant improvement
in terms of controlling HAR. A complementary approach
has focused on eliminating the galactosyl-α-1,3-galactose
antigen from the surface of donor cells. Several groups
achieved this feat by generating pigs without the gene
encoding α-1,3-galactosyltransferase, which is the enzyme
that is required for this sugar modification [38]. This was
accomplished by the serial ‘knockout’ of the gene in
cultured pig fibroblasts, followed by somatic cell nuclear
transfer (SCNT) to generate pigs. This revolutionary
accomplishment marks the beginning of a new era in pig
genetic engineering, providing a path to the generation of
pigs based on both gene supplementation and ablation.
Pig cells are also a promising resource to counter the limited
supply of human tissues for cell-based therapy, particularly
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Total 95,708neurologic disorders and diabetes. Recent clinical and pre-
clinical trials of islet cell transplantation and xenotrans-
plantation, respectively, suggest that xenogeneic cellular
therapy may indeed provide a viable option for the treatment
of diabetes. Serendipitously, adult pig islets do not express
the galactosyl-α-1,3-galactose epitope. Instead, rejection
[39] of xenogeneic islets in NHPs results from direct or
indirect activation of T cells by donor pig xenopeptides.
Targeted prevention of T cell co-stimulation has led to great
strides in pig islet xenotransplantation to NHPs [40,41].
However, maintenance of immunosuppression puts patients at
risk for opportunistic infections, and can cause significant
cardiovascular, renal, hematologic, gastrointestinal, and (in
female patients) reproductive toxicity [42,43]. Pig transgenesis
could provide an alternative approach to systemic T-cell co-
stimulation blockade, instead relying on the local provision of
immunotherapeutic proteins by the xenograft [44,45].
Prevention of zoonotic transmission of pathogens from
donor pigs to patients is also crucial for clinical application
of porcine xenotransplantation. Although husbandry in a
biosecure environment can eliminate most risk, endogenous
agents such as porcine endogenous retroviruses (PERVs)
require special attention. Indeed, upon co-cultivation of pig
and human cells, PERVs inefficiently traverse the species
barrier [46-48]. Although no evidence of pig to human
transfer has ever been observed in vivo [49-51], it is prudent
to develop pigs with a reduced genetic potential for PERV
transmission [52-56].
Casting pearls unto swine (porcine transgenesis)
Generation of transgenic pigs, like that of other mammals,
has traditionally relied on the introduction of exogenous
DNA expression constructs into the pig genome by
pronuclear injection (PNI) [57]. Although PNI remains the
primary method of mouse transgenesis, low rates of
germline transmission and expensive husbandry costs have
interfered with the widespread application of this technology
to livestock. SCNT has emerged as an excellent alternative to
PNI, boasting transgenesis rates of 100% depending on
selection of donor nuclei. Despite the success of both PNI
and SCNT in pig transgenesis, both methods suffer from an
extremely low transgenesis rate per embryo/ova processed.
Recent successes in the application of lentiviral transduction
to pig transgenesis have demonstrated it to be quite efficient,
and improvements in embryo survival result in transgenesis
efficiencies of about 80% of live-born animals with a
concomitant increase in the rate of transgenesis per embryo
processed [58,59]. Recent results in mice suggest that
coupling PNI with transposon systems also provides a viable
alternative to transgenic pig production. We discuss the
strengths and weaknesses of each of these approaches, and
present an analysis of the value of transposons as tools for
mammalian transgenesis, with an emphasis on pigs (also see
Table 2).
A poke in a pig (pronuclear injection)
PNI was the first method used to produce transgenic pigs
[57]. Generally, this involves surgical harvest of pronuclear
staged embryos from the oviduct of donor animals, injection
of a DNA solution into the male pronuclei, and then transfer
of injected embryos into the oviduct of a recipient female at a
similar stage of estrus. Significant challenges in coordinating
the reproductive cycles of donors and recipients have been
countered with the development of excellent methods for
estrous synchronization and superovulation [60]. Pronuclear
microinjection is further complicated by the presence of a
lipid-laden cytoplasm that obfuscates visualization of the
pronucleus. However, brief centrifugation stratifies the cyto-
plasm, revealing the pronucleus in 66% to 85% of embryos
[61]. Tail-docks, ear-clips, or blood of live-born piglets is
usually screened by either polymerase chain reaction or
Southern blotting to identify transgenic founders and to
eliminate nontransgenic animals from further husbandry.
There are two primary bottlenecks that limit the efficiency of
this approach: embryo survival and the efficiency of trans-
gene integration. In vitro culture and manipulation severely
reduce the survival of injected embryos. Unfortunately,
simply transferring embryos from one pig oviduct to another
results in live-birth rates of only 35% to 40% of transferred
embryos [62]. Microinjection results in only 10% to 15% of
transferred embryos surviving to term [63,64], with
increased losses probably due to physical perturbation of the
cell and toxicity of DNA and associated impurities [65,66].
Transgenesis frequencies per injected embryo have ranged
between 0.24% and 2.6% [67,68], although a transgenesis
rate as high as 4.2% following optimization of DNA
concentration was recently reported [66]. A compromise
between embryo survival and transgenesis is required to
obtain the greatest overall efficiency of transgenic offspring
per injected embryo, because increasing the concentration of
injected DNA enhances transgenesis but reduces the number
of animals born [66]. As discussed below, enzymatic delivery
of transgenes to the genome by transposons may permit the
use of low DNA concentrations, thereby maximizing live-
birth rate without compromising rates of transgenesis.
A notable limitation of PNI is an inability to create allelic
substitution (so-called knock-out or knock-in) by homologous
recombination (HR). Therefore, alternative methods are
required to generate hypomorphic, loss-of-function, or null
pigs depleted of specific gene products. One approach
successfully used in pigs relied on PNI-mediated transgenesis
with a dominant negative transgene [32]. As mentioned above,
Petters and coworkers [32] developed an informative swine
model of retinitis pigmentosa based on directed expression of a
dominant negative allele of the human rhodopsin gene.
However, dominant negative alleles will not be available for
every target and so are likely to be limiting. RNA interference
(RNAi), on the other hand, provides a seemingly universal
method for depleting gene function in swine (for review [69]).
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that responds to double-stranded RNA by sequence-specific
silencing of gene expression. Stable expression of short
hairpin RNA in eukaryotic cells using H1, U6, and 7S K
polymerase III promoters [70,71,] as well as polymerase II
promoters [72], has proven effective in eliminating mRNA
transcribed from targeted genes. Peng and coworkers [73]
recently observed RNAi-mediated mouse phenotypes after
PNI transgenesis without toxicity. Indeed, we were able to
generate gastrointestinal phenocopies of cystic fibrosis in
mice by PNI transgenesis with transposons expressing short
hairpin RNA directed against the cystic fibrosis trans-
membrane regulator (Carlson and co-workers, unpublished
data). These observations, coupled with the demonstrated
efficacy of RNAi in pig cells [33], suggest that RNAi
represents an efficient, dominant, and specific approach to
developing transgenic pigs by PNI or SCNT.
Turning a sow’s ear into a silk purse (somatic cell
nuclear transfer)
SCNT, or cloning, involves the transfer of a somatic cell
nucleus from a donor cell into an enucleated oocyte, fusion
and activation of the reconstructed embryo, and subsequent
transfer to surrogate females to establish pregnancy. Since
its introduction, SCNT has become a popular alternative to
PNI for the addition of transgenes to the pig genome for
several reasons (Table 2). Two of the more notable advan-
tages of SCNT in producing transgenic offspring by gene
addition are the rate of transgenesis among live-born
offspring and the possibility of screening nuclear donor cells
for transgenesis and gene expression before embryo recon-
struction. Depending on the method of donor cell trans-
fection and selection, the transgenesis rate in SCNT piglets
can be 100%. However, considering that only 0.05% to 1.2%
[74,75] of reconstructed embryos will produce live offspring,
the overall rate of transgenesis per reconstructed embryo is
similar to that for PNI. Another advantage of SCNT is the
ready commercial availability of oocytes, which can be
matured in vitro and then enucleated before receiving nuclei
from donor cells.
Although the ability to screen for transgene expression in
donor cells before cloning provides some advantage, given
their restricted lineage, transgene expression in porcine fetal
fibroblasts (PFFs) is frequently not expected to be indicative
of expression in animals derived from them. The most
striking advantage of SCNT is the ability to achieve HR in
cultured donor cells [74,76-79], demonstrated by several
groups focused on eliminating the α-(1,3)-galactosyltrans-
ferase locus. This has important implications for the
knockout or allelic replacement of target genes, although
other loci may be more challenging, given that loci vary in
the efficiency with which they can be targeted [80,81].
Additionally, unlike murine embryonic stem cells, the
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Table 2
Evaluation of methods for swine transgenesis
Pronuclear (naked DNA) Pronuclear (transposon)a SCNT (PFF) Lentiviral
Live-born/embryo manipulated 10% to 15% ND 0.05% to 1.2% 18% to 27%
Transgenic per live-born + ++ +++ ++
Integration preference Random Random/class specific Random or targeted Gene coding regions
Null/hypomorph RNAi/DN RNAi/DN Gene targeting/RNAi/DN RNAi/DN
Cargo size limitationsb ND ND ND About 8 kilobases 
Integrations per live-born Typically 1 1 to 10  Typically 1 1 to 20
Mosaicism Often Often Seldom often
Ease of vector production ++ ++ ++/ (± HR constructs) +
Concatemer instability  Yes No Yesc No
Precision (to the base pair) No Yes Noc Yes
Homologous recombination No No Yes No
Genome aberrations  Yes No No No
Heritable expression ++ +++ ++d ++
Preimplantation screen ± ± ++e ±
Selection required No No Yes No
aAs observed previously in mice. bIncreasing size invariably decreases efficiency. cTargeted alleles are stable. dMosaicism observed in clones of clones
[200]. eExpression in SCNT donor cells does not ensure expression in animal. DN, dominant negative translocations; HR, homologous recombination;
ND, not determined; PFF, porcine fetal fibroblasts; RNAi, RNA interference; SCNT, somatic cell nuclear transfer.window of opportunity for isolating recombined cellular
clones, and thus the complexity of manipulations possible, is
limited by PFF cellular senescence. The limited lifespan of
PFFs has prohibited serial transgenesis, genetic manipula-
tion, or selection cassette recycling in vitro. Although serial
genetic manipulations in pig could be achieved by standard
breeding, this is slow and implies excessive husbandry costs
(>10 months from impregnation to sexual maturity).
Instead, researchers have used an iterative cloning approach,
in which each round of genetic modification requires isola-
tion of fetal fibroblasts, genetic manipulation, re-cloning, re-
implantation, and fetal development [74,79,82]. Despite this
clever solution, inefficiencies in nuclear reprogramming and
SCNT render this approach to creating pigs with complex
genetic manipulations or multiple transgenes difficult and
time consuming. A porcine cellular resource more amenable
to genetic manipulation, less susceptible to cellular senescence,
and more effectively reprogrammed would dramatically
improve the efficiency of complex genetic manipulation in
vitro before SCNT.
Given their potential in terms of long-term culture and their
superiority as nuclear donors [83,84], embryonic stem cells
are a highly desirable resource for pig transgenesis and
cloning. Indeed, successful derivation of germline competent
embryonic stem cells from livestock species has been an
actively pursued goal for many years [85]. Although many
groups have reported isolation of embryonic stem-like cells,
far fewer have produced cells demonstrated to contribute to
chimeric piglets when injected into an early blastocyst
[86,87], and to date no evidence of germline chimerism from
porcine embryonic stem cells has been reported. However,
the recent isolation of multipotent cells from pigs by several
groups may provide alternative cellular resources with many
of the desirable features of embryonic stem cells [88-94],
with the potential to increase the efficiency and complexity
of genetic manipulations by SCNT.
The naked truth about DNA integration
Stable integration and expression of a transgene in the pig
genome requires that several conserved, fundamental
barriers be overcome. The initial barrier is entry of the trans-
gene into a cell, embryo, or ova. This has been accomplished
by either direct microinjection of DNA into cells or ova, by
transfection of cells with DNA complexed with cationic
lipids, polycations, or other conjugating substances, or by
electroporation. Subsequent trafficking of DNA into the
nucleus is not understood, but it may require dissolution of
the nuclear membrane when a cell divides (for review [95]).
Once within the nucleus, the transgene must rely on cellular
machinery to serendipitously insert the transgene into host
chromosomes.
Linearized DNA integrates with an efficiency fivefold greater
than that of supercoiled DNA [96], and so it is preferred for
the generation of transgenic cells and animals. This
observation makes sense, considering that the DNA double
strand break (DSB) repair machinery is responsible for
transgene integration, with nonhomologous end joining
(NHEJ) being the most prominent mechanism [97]. As the
name implies, NHEJ responds to DNA DSBs in cells by
nonhomologous ligation of available DSBs. The introduction
of 104 copies of a transgene into a cell (in the case of PNI)
provides a great deal of substrate for NHEJ, giving rise to
head to tail, multicopy gene arrays (concatemers) of
extrachromosomal DNA before or simultaneous with
integration into chromosomes. NHEJ acts very rapidly in
mouse embryos, with concatemers observed in 100% of
embryos only 5 to 10 min after DNA injection [98]. These
concatemers are either degraded or find their way into the
genome, presumably at a DSB [98], resulting in transgenic
mice carrying a transgene concatemer at one or more loci in
the genome [98-101].
Although use of naked DNA has provided an effective
method for producing transgenic cells and animals, signifi-
cant complications associated with un-facilitated integration
have been described. Concatemerized transgenes are prone
to silencing by the host for several reasons. Flanking GC-rich
bacterial sequences may accompany the transgene cassette,
causing hypermethylation and resulting in transgene
silencing [102,103]. Additionally, the nature of a concatemer
itself (multiple tandem copies of a transgene at a single
locus) can stimulate transgene silencing [104,105] - a
phenomenon that is partially ameliorated by the use of viral
and transposon systems that deliver precise single copies of
transgenes to the genome.
Genetic lesions and instability have also been encountered
with un-facilitated integration of DNA, resulting in deletions
adjacent to the insertion site, chromosomal translocations,
and insertion of additional genomic sequence within a
transgene concatemer [106-110]. These types of genomic
alterations may not be overtly detected, but they could
certainly affect the health of animals produced by PNI or
from genetically modified cells by SCNT. Furthermore,
valuable transgenic animal lines may suffer from transgene
instability, giving rise to rearrangements at the transgene
locus that can result in loss of transgene concatemers
(possibly including flanking DNA), lower than expected
transmission to offspring, somatic mosaicism of F1 progeny,
or increased morbidity [111-113]. In contrast, the precise
integration of transgenes by viral and transpositional
transgenesis provides for reduced concatemer-associated
transgene instability.
Viral transgenesis
Recent publications [58,59] reported a highly efficient
method for transgenic swine production using pseudotyped
lentiviruses. Like PNI, current methods for lentiviral trans-
genesis rely on surgical procurement of early embryos and
implantation into the reproductive tract of a synchronized
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lentivirus is microinjected into the peri-vitelline space of the
early embryo, whereupon the viral machinery mediates
transport of the transgene to the nucleus and integration of
provirus into the pig genome. Peri-vitelline injection is
minimally invasive to the embryo, probably accounting for
enhanced embryo survival (18% to 27%) compared with PNI
and SCNT (Table 2) [58]. In addition, reported rates of live-
born pig transgenesis of 70% [59] and 92% [58] rival those
observed with SCNT, providing an overall transgenesis
efficiency of 13% and 25%, respectively, of transferred embryos
resulting in transgenic piglets. These overall transgenesis rates
are about tenfold better than those with PNI or SCNT on a per
embryo basis. Furthermore, most transgenic F0 animals have
multiple copies of the proviral insert (up to 20 in the report by
Hofmann and coworkers [59]).
Inserting this many transgenes is both good and bad. The
good news is that, with patience, there are many chances to
identify a transgene with an appropriate expression domain.
The bad news is that if anything other than ubiquitous
expression is desired, then identification of a transgene with
an appropriate expression pattern requires breeding to
segregate away other transgene loci. A further complication
is the tendency of lentiviruses to insert into or near
transcriptional units [114,115], increasing the likelihood of
insertional mutagenesis or position effects from nearby
endogenous enhancer elements. Several studies have also
noted an increased likelihood of transgene silencing in the
context of the retroviral genome [116]. In agreement with
this tendency, Hofmann and coworkers [117] observed loss
of transgene expression in one-third of outbred F1 animals
attributed to transgene methylation. However, transgene
expression was consistent between sibling animals carrying
the same insertion, suggesting that expression was fixed for
a specific insertion before germline transmission. Con-
straints on lentiviral cargo capacity (Table 2), the potential
use of cryptic splice signals in the gene expression cassette
during reverse transcription of the viral genome, and a
requirement for viral titers of 109 to 1010 particles per
milliliter all complicate the construction and preparation of
lentiviral transgene vectors. Nevertheless, the efficiency of
transgenesis using this technique is the greatest thus far
reported; it is therefore likely to remain a valuable
implement in the pig genetic engineering toolbox.
Transposons in vertebrates
Transposable elements, especially DNA transposons, have
been used extensively for germline transformation of
invertebrates and plants. Efficient integration of DNA into
the genome is one of the reasons why transposon-based
insertional mutagenesis is an essential component of large-
scale functional genomic efforts in many species, including
bacteria, yeast, insects, and plants [118-123]. The application
of transposons to vertebrate biology began in 1997 with the
‘reawakening’ of the Sleeping Beauty transposon [124]. Ivics
and coworkers [124] reconstructed the SB10 transposase
based on the consensus sequence of inactive transposons
littered throughout several salmonid genomes. The refur-
bished SB10 transposase facilitated efficient gene transfer in
cultured cells from many vertebrate species [125]. Since the
restoration of Sleeping Beauty, other transposon systems
including Tol2 [126,127], piggyBac [128,129], Frog Prince
[130], Minos [131], Himar1 [132], and Passport [133] (Clark
and coworkers, unpublished data) have been used to
transpose DNA into vertebrate cells. DNA ‘cut and paste’
transposons are capable of enzymatically moving a gene
expression cassette from a delivery vector into a host
genome. The transposase binds to the inverted terminal
repeats of the transposon, excises it from its original
location, and integrates it into the genome. Domestication of
transposon systems generally finds them operating as a
binary system: the transposon vector containing the
transgene expression cassette flanked by terminal repeats of
the transposon; and the transposase enzyme, which can be
provided by a second gene expression cassette on the same
(cis) or separate vector (trans), as mRNA [134-136] or
potentially as recombinant protein.
The  Tc1/mariner family of transposons [137], whose
members include Sleeping Beauty,  Frog Prince,  Minos,
Himar1, and Passport, randomly integrate into TA dinucleo-
tides distributed around the genome. Upon integration, the
TA dinucleotide is duplicated at each exterior end of the
inverted terminal repeats. The piggyBac transposon, the
founding member of the piggyBac family of transposons
[138], integrates into a TTAA tetranucleotide, which is
duplicated at each end of the transposon. Tol2, a member of
the hAT family of transposons [139], does not integrate into
a specific target sequence, instead relying on local DNA
deformation [140]; it nonetheless also creates a target site
duplication of eight base pairs at the junction between
transposon and genome. Transposons mobilized by
transposase result in a DSB at the excision site that is
repaired by cellular machinery. The major repair pathway
for Sleeping Beauty is NHEJ, which most often results in
conversion of the original TA dinucleotide to a TACA/TGTA,
although other repair sequences have been observed,
including small insertions and deletions [141,142]. This
canonical footprint results in a five-nucleotide insertion
that would disrupt the coding sequence of an interrupted
open reading frame. Tol2 repair also relies on NHEJ
without a predominant repair sequence because of variance
in target-site sequences. Insertions and deletions have also
been observed after Tol2 excision [143,144]. Mobilization of
the  piggyBac transposon, on the other hand, generally
results in restoration of the duplicated TTAA back to a
single TTAA, leaving no disruption at the excision site
[128]. The clean repair of excised transposons, as well as
piggyBac’s proclivity for landing in genes [145,146] (see
below), suggest that it will be valuable as a reagent for
functional genomics.
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used to produce transgenic animals, including fish, frogs,
mice, and rats [135,136,145,147,148] (Guerts and co-
workers, unpublished data) by pronuclear or cytoplasmic
DNA microinjection. Transposons have also been
remobilized  in vivo from chromosomal locations, often
leading to their vacating the original locus and taking up
residence at a new one. For example, expression of Sleeping
Beauty transposase in the germline of mice has been used to
mobilize transposons previously introduced into the mouse
genome [149-152]. Gene and enhancer trap vectors have
been developed and used for germline mutagenesis in fish
and mice for functional genomic applications [152-158].
Similarly,  Sleeping Beauty vectors have been used to
identify genes that are involved in cancer genesis by causing
activation of proto-oncogenes or interruption of tumor
suppressor genes by remobilization of transposons in
somatic tissues of mice [159,160].
Despite the benefits of transposition, there are perhaps some
limitations. There have been several reports indicating a
decrease in transposition efficiency with increasing trans-
poson size [125,161,162]. However, in all of these cases the
influence of plasmid size on transfection was not accounted
for, despite the fact that even small differences in plasmid
size can alter transfection efficiency [163]. Where trans-
position can be observed without being confounded by
transfection, for example in PNI or upon mobilization from a
genomic context, large transposons appear to mobilize with
nearly the same efficiency as do smaller ones [145,158]. As
mentioned above, some transposons prefer to integrate into
transcription units. This can be either a benefit or a
disadvantage, depending on whether the goal is to mutate
genes or to safely deliver a transgene. In this case, having
multiple transposon systems available may permit selection
based on the application and the temperament of a
particular transposon. For instance, at first glance piggyBac
appears to integrate preferentially into or very near
transcription units, landing in them as much as 67% of the
time [145,146]. By contrast, Sleeping Beauty does not
integrate into transcription units at a rate much higher than
what would be expected by random integration [164].
Genetic engineering with site-specific recombinases
Site-specific recombinases, such as the P1 bacteriophage
cyclization recombinase enzyme (Cre) and flippase (Flp)
from Saccharomyces cerevisiae, have revolutionized genetic
engineering by allowing efficient and accurate manipulation
of the genome by site-directed deletion, inversion, insertion,
or chromosomal exchange (for review [165]). The use of
recombinases and their recognition sites in trans has
allowed the development of ‘genetic switches’ for the
conditional activation or inactivation of gene expression.
Specific and complex control of transgene expression can be
achieved in a manner that is dependent on the spatio-
temporal expression domain of the recombinase(s). The
ability to express the recombinase from tightly regulated
spatially or temporally restricted promoters has allowed
investigation of gene function beyond their initial develop-
mental role, potentially lethal as a null, and to examine the
role played by a gene product in specific tissues in late-stage
embryos or adults.
Application of transposons and recombinases
for genetic engineering of pigs
Transposons and recombinases for mobilizing
transgenes in pig cells
We recently reported, for the first time, transpositional
transgenesis in pig cells using Sleeping Beauty,  Passport,
Tol2, and piggyBac transposon systems [166]. Initial assess-
ment of these transposons relied primarily on a porcine
endometrial glandular epithelial (PEGE) cell line [167],
which is one of very few immortalized cellular resources
available for pigs. In PEGE cells, transposons increased
cellular transgenesis from 5-fold to 28-fold above back-
ground, depending on which transposon system was used. In
addition to the baseline enhancement of transgenesis
measured by clone formation, transposons differed in their
robustness of integration, as indicated by the number of
integrations per clone, which ranged from 1 to 15. Southern
analysis of cellular clones revealed that the vast majority of
transgene insertions resulted from transposition, a fact
borne out by analysis of the junctions between transgene
and the genome for each class of transposon. Without
optimization in PEGE cells, piggyBac and Tol2 transposon
systems were more active than Sleeping Beauty, which was
more active than Passport. The Passport transposon system
relies on wild-type sequences isolated from the Pleuronectes
plattesa genome, representing the only vertebrate Tc1-type
transposon thus far found to be active in its native form
(Clark and coworkers, unpublished data). Its activity could
probably be improved by engineering of its inverted terminal
repeats or transposase, analogous to improvements made to
the  Sleeping Beauty system [168]. Additional hyperactive
mutants of Sleeping Beauty might also be more active in pig
cells [169-171]. However, although it may be possible to
further improve transposon systems for application to PEGE
cells, transposon efficiency varies depending on the cell type
[125,129,130]. Therefore, the relative activity of any
transposon system in different pig cells, including pig
embryos, requires further investigation. It is likely that,
depending on the application, there will be distinct and
overlapping roles for a variety of transposon systems in
swine genetics (Figure 1). It is therefore quite promising that
four unique transposon systems result in enhanced trans-
genesis as well as precise integration of expression cassettes
into one or more genomic locus in swine.
In addition to characterizing the activity of four vertebrate
transposons in porcine cells, Clark and coworkers [166] also
demonstrated for the first time the ability of Cre and Flp
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pig genome. Both Cre and Flp recombinase were functional
in pig cells, as indicated by their ability to remove a positive-
negative selection cassette from episomal and numerous
genomic locations. In addition, a Cre-dependent genetic
switch was demonstrated to be effective in mediating
conditional gene expression from episomal and genome-
resident transposons. This study provides the basis for
developing transposon and recombinase based tools for
genetic engineering of the swine genome.
Transposition and recombination for porcine somatic
cell nuclear transfer
The first step in creating transgenic pigs by SCNT involves
the transgenesis of cells that will serve as nuclear donors.
This generally involves transfecting or electroporating PFFs
or another suitable cell type with DNA expression
constructs. Most if not all transgenesis by SCNT involves the
co-delivery (in cis or  trans) of a selectable marker for
enrichment of transgenic cells destined to serve as nuclear
donors. Certainly, this in not the limiting step in producing
transgenic pigs by SCNT. However, the routine use of
transposons would increase the efficiency of cellular trans-
genesis while avoiding concatemerization and integration of
CpG-rich vector sequences. Since the production of
transgenic swine can be quite expensive, any advantage with
regard to stable transgene expression should be exploited. In
addition, the introduction of multiple, unlinked transgenes
by transposition could increase the value of founder pigs,
although breeding would be required to segregate these loci.
The most compelling application of recombinases in porcine
SCNT relates to selection cassette recycling. Elimination of
selectable marker genes from prospective donor cells simpli-
fies genotype-phenotype correlations and eliminates the
potential for selection cassette interference [172] on trans-
gene expression. It would of course be important to minimize
the presence of extraneous DNA (especially antibiotic
resistance genes) from genetically modified pigs were they
ever to be considered for entry into the food chain. The use
of a positive/negative selectable transgene such as PuroΔTK
or HygroCodA [173,174] flanked with recombinase
recognition site (RRS) provides a facile substrate for marker
removal using site-specific recombinases before SCNT
(Figure 2). Unfortunately, because their tendency toward
senescence, the most commonly used cellular resource for
SCNT (PFFs) are not amenable to the extended culture
required for multiple rounds of drug selection. Recently
developed mesenchymal and multipotent stem cells from
pigs may provide a solution to this dilemma, because they
appear to be amenable to extended culture [89-91,175,176],
genetic manipulation [88,92,177], and use as nuclear donors
for SCNT [92-94]. Elimination of RRS flanked selection
cassettes could also await breeding of cloned transgenic pigs
to a line of pigs that express Cre or Flp recombinase in their
germline (Figure 2).
Similar strategies for selection cassette recycling can be used
after homologous recombination if gene targeting vectors
are designed with RRS flanking positive/negative selectable
markers (Figure 3). A simple case of selection cassette
recycling requires flanking a positive/negative selectable
marker, such as PuroΔTK or HygroCodA [173,174], with RRS
sites (Figure 3b). In addition to RRS sites, the gene targeting
vector must contain a unique negative marker (not part of
the positive/negative marker) for counter-selection against
random integration; this could be CodA, TK, or diphtheria
toxin [178]. After selection of homologous recombinants, the
cells can be transfected with Cre and selected for loss of the
positive/negative marker (gancyclovir for PuroΔTK). Cells
that lose the selection cassette will grow and can be used for
nuclear donors before SCNT. Alternatively, the selection
cassette can be removed after SCNT by crossing transgene
carriers to pigs expressing Cre recombinase or by delivering
recombinase transiently in carrier embryos by micro-
injection of Cre mRNA or protein.
In addition to selection cassette recycling, recombinases can
be used to create conditional nulls following gene targeting
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Figure 1
Applications of transposition to porcine transgenesis. Presented is flow
diagram of the primary steps involved in the production of transgenic pigs
by somatic cell nuclear transfer (SCNT), pronuclear injection (PNI), and
lentiviral transduction (LVT). Each procedure requires the surgical
isolation of oocytes or embryos. SCNT requires the production of
transgenic donor cells, which can be augmented by transposon-mediated
transgenesis (TnT). The donor cells are injected into enucleated oocytes,
which are then fused and activated before embryo transfer into a
recipient. PNI involves the injection of DNA into the male pronuclei
before nuclei fusion. PNI can be augmented by TnT. LVT occurs by
injection into the peri-vitelline space of staged embryos. In all cases
manipulated embryos are surgically implanted into a synchronized
recipient sow. A portion of the recipient sows will maintain pregnancy
until parturition. The piglets can then be screened for the presence of the
transgene by polymerase chain reaction, Southern hybridization, or
detection of marker gene expression.(Figure 3c). In this case two sets of RRSs are used. The first
set flanks the positive/negative selectable marker for
selection cassette recycling to ensure that there is no
impairment of gene function at the locus. Ideally, the
selection cassette would be removed in vitro before SCNT,
but this could also be done in pig, as described above. The
second set of RRS flanks a critical element of the locus, for
example an exon within the coding region. The conditional
knockdown of the locus can then be achieved by crossing the
conditional null carrier to pigs expressing Cre in a desired
manner.
Transposition and recombination for porcine
pronuclear injection
The combination of transposons and recombinases may also
greatly increase the efficiency and complexity of transgenic
pig production by PNI. Sleeping Beauty, Tol2, and piggyBac
transposons have all been used for germline transformation
of multiple species by PNI and cytoplasmic microinjection,
at a rate far superior to unfacilitated DNA injection. In
particular Sleeping Beauty and piggyBac transposons have
been used for the generation of transgenic mice by PNI.
Dupuy and coworkers [136] saw the rate of transgenic live-
born pups increase from 29% up to 45% using the Sleeping
Beauty transposon system. Ding and colleagues [145] saw
increases in mouse embryo transgenesis rates from 10% to
35%, from 18% to 66%, and from 5% to 46% after PNI with
three transposons when piggyBac transposase was included.
In addition, with reports of increased transposition using
methylated Sleeping Beauty transposons that were
methylated in vitro before transfection [179], Geurts and co-
workers (unpublished data) tested the influence of this
treatment on the efficiency of mouse transgenesis by PNI.
This preliminary experiment yielded an unprecedented live-
born transgenesis rate of 90%, with integrations that were
later transmitted to F1 mice and shown to express in a locus-
dependent manner. The fact that four transposon systems
were recently demonstrated to be active in pig cells bodes
well for their application to porcine transgenesis by PNI. A
modest improvement in the rate of swine embryo
transgenesis using transposons could have a significant
impact on the efficiency of swine engineering for agricultural
and medical applications. The observation of multiple
transposed integrations in pig cells (1 to 15) and in
transgenic mouse embryos and pups (1 to 10) also suggests
that it will be possible to create pigs with multiple stable,
unlinked, and reliably expressed transgenes using one or
more transposon system [145] (Clark and coworkers,
unpublished data).
There are a number of reasons to include RRS in transposons
to be used for PNI. Selection cassette recycling is mentioned
above. In addition, to circumvent unsuspected deleterious
effects of ubiquitously expressed transgenes, it may be
desirable to include conditional (recombinase-activated) gene
expression cassettes (Figure 4). For example, a transgene
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Figure 2
Selection cassette recycling of selectable marker in pigs. A transposon containing two genes, a transgene of interest (‘gene’, red) and a selectable marker
(‘marker’, green) can be used to construct a transgenic pig. The promoters can differ for the two genes. Generally, the marker will be driven by a
ubiquitous promoter (Ub), allowing selection for expressing donor cells (somatic cell nuclear transfer [SCNT]) or piglets (pronuclear injection [PNI] or
lentiviral transduction [LVT]), whereas the promoter for the transgene could be a ubiquitous promoter or tissue-specific promoter (TSP). In the diagram
the ‘gene’ is driven by a TSP. Expression in an F0 animal is depicted by the pig on the left with the marker being expressed ubiquitously and the transgene
being expressed in a tissue-specific manner, shown here as pancreatic expression. Crossing this pig to a pig that ubiquitously expresses Cre recombinase
(blue) would result in F1 progeny that lost expression of the ubiquitous marker and retained expression of the transgene in the pancreas. Ubiquitous Cre
expression would occur in the F1 (50% or 100%, depending on whether the Cre pig was heterozygous or homozygous), but this would be irrelevant to
analysis of the F1 phenotype. RRS, recombinase recognition site.encoding a visibly or systemically detectable protein (for
example, green fluorescent protein or secreted alkaline
phosphatase) could be expressed in the default state (either
ubiquitously or in specific tissues), potentially facilitating the
identification of transgenic piglets. Conditional juxtaposition
of the downstream transgene could be activated in later
generations by crossing to a pig that expresses Cre
recombinase ubiquitously or in a tissue-specific manner.
A role for transposons in somatic cell therapies
Porcine models of gene therapy
In addition to the germline transformation, transposon
systems can increase the stable integration of transgenes
into somatic cells. In fact, the Sleeping Beauty transposon
system is actively being developed for several gene therapy
applications. Currently, much of this work is being done in
rodent models with successful long-term expression of
therapeutic transgenes [180-188]. However, the methodo-
logy of gene delivery, clinical dosage, and efficacy of
treatments in the mouse may not be directly applicable to
treatment of human patients. It is therefore likely that large
animal models will be important in advancing clinically
relevant gene therapy protocols. Pigs have been used to
improve  surgical techniques for years because of their
similarity in size and physiology to humans, as well as their
widespread availability as an accepted part of the human
food chain. It is therefore quite reasonable to test gene
therapy protocols in pigs. For example, hydrodynamic
delivery of DNA by the injection of a large volume of DNA
solution into the tail-vein of mice results in significant DNA
uptake into the liver [180]; however, this technique is
unlikely to be directly scalable to large animals or humans.
DNA has successfully been delivered by local hydrodynamic
injection into pig arterial vessels [189] and muscle [190],
although - as expected for naked DNA - the expression was
short lived. Perhaps similar local hydrodynamic delivery
coupled with transposons could allow selective uptake and
maintained expression by these tissues or other targets, such
as liver, without the need for systemic injection of large
volumes of fluid. Pigs may also provide an ideal large animal
model for testing the efficacy of reagents being developed for
systemic delivery of therapeutic genes to specific tissues or
organs.
The potential tractability of pigs for development of large
animal models of human disease makes them an attractive
system not only for developing gene delivery protocols but
also for testing the efficacy of these regimens in curing
disease. For example, the National Swine Research and
Resource Center is currently developing pig models of cystic
fibrosis based on gene knockout and transposon-based RNAi
[33]. These pigs not only may provide the first animal model
of the cystic fibrosis pulmonary phenotype, but they may
also be ideal for the development of gene therapy protocols
to treat this devastating disease.
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Figure 3
Selection cassette recycling after homologous recombination. (a) An
illustration of a typical homologous recombination event utilizing a
positive/negative selection scheme. The gene sequence is shown with
exons 2, 3, and 4. The targeting vector replaces exon 3 with a positive
selectable marker, such as the PGK driven neomycin resistance cassette
(phosphoglycerate kinase [PGK]-neoR), and utilizes a negative selectable
marker, such as the herpes simplex virus promoter driven thymidine
kinase gene (HSV-TK), to counter-select against random integration of the
targeting vector. Homologous recombination results in replacement of
exon 3 with the PGK-neoR cassette. (b) The use of site-specific
recombinases such as Cre or Flp allows removal of a selection cassette
before or after the production of an animal by SCNT. In order to
accomplish this, positive marker is flanked by recombinase recognition
sites like loxP. After homologous recombination (HR) the selection
cassette can be removed by Cre recombinase in culture or in vivo. In order
to select efficiently for removal of the selection cassette in vitro, a
positive/negative selectable marker such as PuroΔTK or hygroCodA, with
the negative selection marker outside the homology arms (for example,
CodA, TK, or diphtheria toxin). (c) Schematic for generating conditional
knockout alleles using site-specific recombinases Cre and Flp. A targeting
construct is generated that leaves each exon intact, but includes loxP sites
flanking an exon critical for gene function, in this case exon 3 (wild-type or
an alternative allele). The selectable marker, flanked by frt sites, can be
removed from the targeted allele either in vitro or in vivo to avoid selection
cassette interference of the modified allele. Animals carrying this targeted
modification can be crossed to animals that express Cre ubiquitously or in
a specific tissue, resulting in progeny with a deletion of exon 3 in the
whole animal or in a specific tissue.DNA vaccination
The evolutionary speed of viruses and bacteria challenges our
ability to develop efficacious protein-based vaccines. Molecular
biology, on the other hand, provides a rapid approach to the
cloning and expression of potential antigens. The promise of
DNA as a pharmaceutical has been actively pursued since the
observation that naked DNA injection into muscle can direct
the production of protein [191]. Applications in gene therapy
and vaccination have been extensively explored, stimulated
by the fact that DNA can be prepared in large quantities in
compliance with cGMP standards, and in a lyophilized form
independent of the traditional cold chain. Although both
humoral and cellular immune responses can be mobilized
with DNA vaccines, problems with DNA delivery and the
intercellular trafficking of antigen have limited their success
[192]. To date, only two DNA vaccines have been licensed for
use in animals; a DNA vaccine to protect farmed salmon and
trout from infectious hematopoietic necrosis virus, and one to
protect horses from West Nile virus [193,194]. Recent
findings suggest that transposons may provide for more
efficient and longer lasting cellular transgenesis to increase
the expression and intercellular trafficking of antigens.
Indeed, in the context of developing transposon-based
reagents for gene therapy, a robust immune response to the
expression of genes from Sleeping Beauty transposons
encoding either clotting factor VIII [186] or iduronidase [195]
have been observed in mice. Given that transposons are
active in pig cells, swine could serve as excellent preclinical
models for human vaccine development, in addition to their
obvious importance in the development of vaccines targeted
against pathogens important to swine production.
High on the hog (conclusions and horizons)
The relevance of pigs to agriculture and medicine makes
them unique among large animal models. With the complete
sequence of their genome soon to be delivered, pigs are
likely to play an increasing role in defining gene function in
human disease using reverse genetic approaches. The use of
enzymatic approaches such as transposition and recombina-
tion should expand the ease and complexity of genetic
modifications available with which to engineer the pig to
model human disease and to produce agricultural and
biomedical products.
In addition, pigs may also be amenable to forward genetic
screens because of reproductive fecundity (about ten piglets
per litter) that rivals that of mice. With appropriate planning
and coordination, and the use of clever molecular reagents,
conducting a mutagenesis screen in pigs could provide
important information about gene function in large animals.
Some cancers and age-related disease etiologies, as well as
therapies for treating them, might be better studied in pigs,
which commonly live to be ten years old and, in rare
exceptions, into their second decade.
Transposons are ideal for use as insertional mutagens,
particularly piggyBac, which tends to land in transcription
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Figure 4
Conditional activation of transgenes in pigs. A transposon containing a Cre-activatable transgene (‘gene’, red) interrupted by a selectable marker gene
(‘marker’, green) can be used to obtain transgenic pigs with conditional expression of a transgene. The promoter driving expression of the marker/gene
can be either ubiquitous (Ub) or tissue-specific (TSP), which would result in the ubiquitous or tissue-specific expression of the marker in F0 pigs, as
shown (green) to the left. Tissue-specific activation of the transgene can be accomplished in two ways: by crossing pigs that ubiquitously express the
marker-interrupted transgene with a pig expressing Cre (blue) in a tissue-specific manner, or by crossing pigs that express the marker-interrupted
transgene in a tissue-specific manner with a pig that ubiquitously expresses Cre. Controlled expression of the transgene or controlled excision of the
marker allows expression of the transgene (to the right, red) in a specific tissue, shown here to represent the pancreas.units and can later be excised for reversion analysis.
Specialized ‘trapping’ vectors based on transposons are able
to cause mutations efficiently upon insertion into a trans-
cription unit, and make identification of the interrupted
gene straightforward [152,153,156,158,196,197]. Transposon-
based mutagenesis screens in mice have generally relied first
on the generation of two mouse strains: one transgenic for a
mutagenic transposon vector (usually in the form of a
concatemer) and another strain transgenic for the corres-
ponding transposase expression construct [149,150,158].
Breeding these lines together provides doubly transgenic
‘seed’ mice, in which germline mobilization of the trans-
poson provides for the recovery of mutated loci in an out-
crossed generation. However, with a 4-month gestation
period and 6 months to sexual maturity, mutagenesis in pigs
using this strategy would require a minimum of 4 years
before mutations could be bred to homozygosity and a
screen initiated.
More immediate would be to use a strategy recently applied
in zebrafish [157,197], which treats the injected generation
as seed stock by supplying both transposon and transposase.
Given a reasonable rate of transgenesis by transposon-based
PNI of pig embryos, mutant alleles could be bred to
homozygosity and a screen initiated within 2 years. Each F0
could be a source of 1 to 15 transposon insertions, with about
12% to 25% of the integrations ‘trapping’ a transcription unit
[145,153,164]. The direct injection method will provide proof
of principle in the shortest amount of time. However, the
longer initial investment required for the production of
double-transgenic ‘seed’ boars would be rewarded by a
nearly constant supply of novel gene traps due to re-
mobilization of transposons in the male germline. Addition-
ally, improvement in the efficiency of cloning and the
availability of porcine stem cells allows another attractive
approach. Development of a library of ‘trapped’, character-
ized, and catalogued pig stem cell clones could provide an
on-demand resource for the generation of pigs by SCNT,
analogous to strategies used for generating mice from
‘trapped’ embryonic stem cell clones [198]. Using this
approach, transposon-trapped alleles could be bred to
homozygosity and a phenotypic analysis begun in pigs in less
than 1 year. In the woven words of Charlotte the spider, the
unique contributions of such pigs would surely reveal dear
Wilbur to represent ‘Some Pig’ [199].
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